课题基金 / 基金详情

项目摘要

项目成果

Binbing Yu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Study 1: Estimating diagnostic accuracy of a multi-stage screening procedure. Summary: In studies to ascertain true disease status, a definitive diagnostic test often is too invasive or expensive to be applied to all subjects, in which case a two-phase design is often used. The results for all subjects from the Phase 1 test, which is inexpensive and non-invasive, are used to determine which subjects will receive the gold standard test in a later phase. Analysis restricted only to verified cases leads to verification bias. The multiple phase design has been used in studies of dementia and in the diagnosis and screening of many other diseases, e.g., colorectal and breast cancer. The design usually involves more than two phases. For example, in a three-phase study the prevalent test in Phase 1 usually has high sensitivity, but relatively low specificity; Phase 2 consists of a second application of the screening test or a more confirmatory test; and the test in the final phase is the gold standard. In this paper, we proposed a method of estimating the parameters of test efficacy and the ROC curves for continuous screening tests in a multiple-phase study in the presence of verification bias. The verification process and efficacy of the screening test could also depend on covariates. We evaluated estimates of parameters of test efficacy after adjusting for verification bias, and we compared different schemes for combining the sequential tests using empirical studies. If we assume the people with unverified dementia status as non-demented, we tend to be optimistic about the ROC curve. For example for a subject who is 70 years old with no education, using a cut-off at 75 yields FPR=0.42 and TPR=0.64. If we ignore the verification bias, then FPR=0.39 and TPR=0.96, which over-estimates the specificity. Comparing Figure4 a-d, we see that education level has a remarkable impact on test accuracy if the cut-off of 75 is used, but there is not much difference for different ages. For the subject who is 70 years old and has 10 years of education, the FPR is 0.05 and TPR is 0.30 for the cut-off of 75. So the screening test using the cut-off of 75 has a high sensitivity and relatively low specificity for subjects with a 10-year education. For subjects with low education, both sensitivity and specificity are moderate. In terms of AUC under the ROC curve, the CASI test performed better for subjects with higher education. Study 2. Estimating the diagnostic accuracy of composite decision rules Screening is a very important step to reduce morbidity or mortality from the disease by detecting diseases in their earliest stages. It is not unusual that several diagnostic tests are performed or multiple disease markers are available for the same individuals. There has been extensive work on the development of methodology for combining information from multiple tests to optimize diagnostic accuracy. Linear combination is a popular method of combining multiple tests by creating a risk score. In clinical settings, the decision rules used in diagnosis are usually more complicated. For example, if the disease is identified by a sequential multi-phase screening procedure, a subject who is screened negative by an initial test in early phase does not go through another screening test in the next phase. In a combined screening for breast cancer with ultrasound and mammography, the screening result is positive if either the ultrasound or the mammogram is positive. In such scenarios, the believe-the-positive (BP) and believe-the-negative (BN) rules, instead of the linear combination, are commonly used by physicians and clinicians. Our goal is to develop a technique to estimate the overall accuracy of a diagnostic procedure as well as the accuracy of each single test when composite decision rules are used to determine disease status. Copula is a popular multivariate modeling tool when the assumption of joint normality is not satisfied. The copula model has found many successful applications in various fields, e.g., actuarial science and survival analysis. We extend the use of semiparametric copula models (SCM) to multiple tests in disease diagnosis. We assume that the marginal distributions of the diagnostic tests are related to the covariates by regression and the associations among the tests are parameterized separately from the marginal distribution by a copula.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/j.1541-0420.2009.01261.x
发表时间: 2010-03
期刊: Biometrics
影响因子: 1.9
作者: [Yu B, Ghosh P]
通讯作者: Ghosh P
DOI: --
发表时间: 2009-05
期刊: Statistica Sinica
影响因子: 1.4
作者: [Hyune-Ju Kim;Binbing Yu;E. Feuer]
通讯作者: Hyune-Ju Kim;Binbing Yu;E. Feuer
DOI: 10.1002/sim.4203
发表时间: 2011-06-30
期刊: STATISTICS IN MEDICINE
影响因子: 2
作者: [Yu, Binbing, Zhou, Chuan, Bandinelli, Stefania]
通讯作者: Bandinelli, Stefania
Approximating the risk score for disease diagnosis using MARS.
使用 MARS 估算疾病诊断的风险评分。
DOI: 10.1080/0266476yyxxxxxxxx
发表时间: 2009
期刊: Journal of applied statistics
影响因子: 1.5
作者: [Yu,Binbing]
通讯作者: Yu,Binbing
Estimating relative risks for longitudinal and clustered binary data
  • 批准号:
    8336694
  • 项目类别:
  • 资助金额:
    $2.76万
  • 财政年份:
    --
  • 负责人:
    Binbing Yu
  • 依托单位:
Evaluatiing the accuracy of complex screening or diagnostic procedures
  • 批准号:
    8336693
  • 项目类别:
  • 资助金额:
    $41.38万
  • 财政年份:
    --
  • 负责人:
    Binbing Yu
  • 依托单位:
Regression analysis in the presence of multicollinearity in brain substructures
  • 批准号:
    8554066
  • 项目类别:
  • 资助金额:
    $4.95万
  • 财政年份:
    --
  • 负责人:
    Binbing Yu
  • 依托单位:
Estimating relative risks for longitudinal and clustered binary data
  • 批准号:
    8554065
  • 项目类别:
  • 资助金额:
    $4.95万
  • 财政年份:
    --
  • 负责人:
    Binbing Yu
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: